March 1, 2018 09:15 AM EST
Pharma

It’s of­fi­cial: EMA to move in­to per­ma­nent Am­s­ter­dam premis­es in No­vem­ber ‘19 amid con­tin­ued protests from Italy

Amber Tong

Al­most four months af­ter the fate­ful “coin toss” that de­cid­ed the EMA’s re­lo­ca­tion to Am­s­ter­dam, the (cur­rent­ly) Lon­don-based reg­u­la­to­ry agency has for­mal­ly ham­mered out a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

New fund will pres­sure flail­ing biotechs, as in­vestor frus­tra­tion boils over

FDA chief Makary talks ex­pe­dit­ing drug ap­provals, RIFs and the abor­tion pill

Ake­so shares new da­ta sug­gest­ing it can beat Keytru­da on sur­vival, wins Chi­na ap­proval

Paul Stof­fels on re­tir­ing from Gala­pa­gos; Boehringer In­gel­heim switch­es up lead­er­ship

J&J re­ports dura­bil­i­ty da­ta for blad­der can­cer 'pret­zel' drug af­ter FDA fil­ing

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times